Genetic background of cholesterol absorption effi cacy. the role of Niemann-Pick C1-like 1 receptor and its genetic variation in lipid metabolism;A koleszterinfelszívódás hatékonysá gának genetikai háttere. A Niemann-Pick C1-like-1 receptor és génvariációinak szerepe a lipidanyagcseré ben

Orvosi Hetilap

Volumn 151, Issue 34, 2010, Pages 1376-1383

  Harangi, Mariann ^a   Balogh, István ^a   Harangi, János ^b   Paragh, György ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Research Laboratory for Chromatography   (Hungary)

Author keywords

cholesterol; ezetimibe; lipid metabolism; Niemann Pick C1 like 1 receptor; plant sterols

Indexed keywords

EZETIMIBE; MEMBRANE PROTEIN; NIEMANN PICK C1 LIKE 1 RECEPTOR; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; CARRIER PROTEIN; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; NPC1L1 PROTEIN, HUMAN; NPC1L1 PROTEIN, MOUSE;

CHOLESTEROL TRANSPORT; DRUG MECHANISM; DRUG TARGETING; GENETIC POLYMORPHISM; HUMAN; INTESTINE CELL; LIPID METABOLISM; PROTEIN EXPRESSION; REVIEW; ANIMAL; DRUG EFFECTS; GENETICS; INTESTINE ABSORPTION; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL TRANSPORT; CHOLESTEROL; ENTEROCYTES; HUMANS; INTESTINAL ABSORPTION; LIPID METABOLISM; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS;

EID: 77955628925     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2010.28933     Document Type: Review

References (46)

1. Daniels, T. F., Killinger, K. M., Michal, J. J. ér mtsai: Lipoproteins, cholesterol homeostasis and cardiac health. Int. J. Biol. Sci., 2009, 5, 474-488.
2. Levy, E., Spahis, S., Sinnett, D. ér mtsai: Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol., 2007, 18, 310-318.
3. Goldstein, J. L., Brown, M. S.: Regulation of the mevalonate pathway. Nature, 1990, 343, 425-430.
4. Santosa, S., Varady, K. A., AbuMweis, S. ér mtsa: Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci., 2007, 80, 505-514.
5. Bosner, M. S., Lange, L. G., Stenson, W. F. ér mtsa: Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J. Lipid Res., 1999, 40, 302-308.
6. Cook, R. P.: Cholesterol. Distribution of sterols in organisms and in tissues. In: Cholesterol. Chemistry, biochemistry, and pathology. Ed.: Cook, R. P. New York, Academic Press, 1958, 145180.
7. Wang, D. Q.: Regulation of intestinal cholesterol absorption. Annu. Rev. Physiol., 2007, 69, 221-248.
8. Miettinen, T. A., Tilvis, R. S., Kesaniemi, Y. A.: Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. Epidemiol., 1990, 131, 20-31.
9. Altmann, S. W., Davis, H. R. Jr., Zhu, L. J. ér mtsai: Niemann- Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science, 2004, 303, 1201-1204.
10. Davis, H. R. Jr., Zhu, L. J., Hoos, L. M. ér mtsai: Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem., 2004, 279, 33586-33592.
11. Davies, J. P., Scott, C., Oishi, K. ér mtsai: Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J. Biol. Chem., 2005, 280, 12710-12720.
12. Lo, C. M, Nordskog, B. K., Nauli, A. M. ér mtsai: Why does the gut choose apolipoprotein B48 but not B100 for chylomicron formation? Am. J. Physiol. Gastrointest. Liver. Physiol., 2008, 294,, G344-G352.
13. Yu, L., Hammer, R. E., Li-Hawkins, J. ér mtsai: Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc. Natl. Acad. Sci. USA, 2002, 99, 1623716242.
14. Lee, M. H., Lu, K., Hazard, S. ér mtsai: Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet., 2001, 27, 79-83.
15. Berge, K. E., Tian, H., Graf, G. A. ér mtsai: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science, 2000, 290, 1771-1775.
16. Yu, L., Bharadwaj, S., Brown, J. M. ér mtsai: Cholesterol- regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J. Biol. Chem., 2006, 281, 6616-6624.
17. Garcia-Calvo, M., Lisnock, J., Bull, H. G. ér mtsai: The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA, 2005, 102, 8 1 32-8137.
18. Davis, H. R. Jr., Hoos, L. M., Tetzloff G. ér mstai: Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol., 2007, 27, 841-849.
19. Knopfel, M., Davies, J. P., Duong, P. T. ér mtsai: Multiple plasma membrane receptors but not NPC1L1 mediate high-affinity, ezetimibe-sensitive cholesterol uptake into the intestinal brush border membrane. Biochim. Biophys. Acta, 2007, 1771, 11401147.
20. Van Heek, M., France, C. F., Compton, D. S. ér mtsai: In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharmacol. Exp. Ther., 1997, 283, 157-163.
21. Rosenblum, S. B., Huynh, T., Afonso, A. ér mtsai: Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxy- propyl]-(4S)-(4- hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem., 1998, 41, 973-980.
22. Clader, J. W.: The discovery of ezetimibe: a view from outside the receptor. J. Med. Chem., 2004, 47, 1-9.
23. Carstea, E. D., Morris, J. A., Coleman, K. G. ér mtsai: Niemann- Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science, 1997, 277, 228-231.
24. Loftus, S. K., Morris, J. A., Carstea, E. D. ér mtsai: Murine model of Niemann-Pick C disease: mutation in a cholesterol home- ostasis gene. Science, 1997, 277, 232-235.
25. Davies, J. P., Levy, B., Ioannou, Y. A.: Evidence for a Niemann- Pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics, 2000, 65, 137-145.
26. Davies, J. P., Ioannou, Y. A.: The role of the Niemann-Pick C1- like 1 protein in the subcellular transport of multiple lipids and their homeostasis. Curr. Opin. Lipidol., 2006, 17, 221-226.
27. Davies, J. P., Chen, F. W., Ioannou, Y. A.: Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science, 2000, 290, 2295-2298.
28. Radhakrishnan, A., Sun, L. P., Kwon, H. J. ér mtsai: Direct binding of cholesterol to the purified membrane region of SCAP: mechanism for a sterol-sensing domain. Mol. Cell., 2004, 15, 259-268.
29. Kuwabara, P. E., Labouesse, M.: The sterol-sensing domain: multiple families, a unique role? Trends Genet., 2002, 18, 193201.
30. Duval, C., Touche, V., Tailleux, A. ér mtsai: Niemann-Pick C1 like 1 gene expression is down-regulated by LXR activators in the intestine. Biochem. Biophys. Res. Commun., 2006, 340, 12591263.
31. Pramfalk, C., Jiang, Z. Y., Cai, Q ér mtsai: HNF1 alpha and SREBP2 are important regulators of NPC1L1 in human liver. J. Lipid. Res., 2010, 51, 1354-1362.
32. Iwayanagi, Y., Takada, T., Suzuki, H.: HNF4alpha is a crucial modulator of the cholesterol-dependent regulation of NPC1L1. Pharm. Res., 2008, 25, 1134-1141.
33. Weinglass, A. B., Kohler, M., Schulte, U. ér mtsai: Extracellular loop C of NPC1L1 is important for binding to ezetimibe. Proc. Natl. Acad. Sci. USA, 2008, 105, 11140-11145.
34. Simon, J. S., Karnoub, M. C., Devlin, D. J. ér mtsa: Sequence variation in NPC1L1 and association with improved LDL-cho- lesterol lowering in response to ezetimibe treatment. Genomics, 2005, 86, 648-656.
35. Cohen, J. C., Pertsemlidis, A, Fahmi, S. ér mtsai: Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc. Natl. Acad. Sci. USA, 2006, 103, 1810-1815.
36. Zhao, H. L., Houweling, A. H., Vanstone, C. A ér mtsai: Genetic variation in ABC G5/G8 and NPC1L1 impact cholesterol response to plant sterols in hypercholesterolemic men. Lipids, 2008, 43, 1155-1164.
37. Martin, B., Solanas-Barca, M., Garcia-Otm, A L. ér mtsai: An NPC1L1 gene promoter variant is associated with autosomal dominant hypercholesterolemia. Nutr. Metab. Cardiovasc. Dis., 2010, 20, 236-242.
38. Chen, C. W., Hwang, J. J., Tsai, C. T. ér mstai: The g.-762T>C polymorphism of the NPC1L1 gene is common in Chinese and contributes to a higher promoter activity and higher serum cholesterol levels. J. Hum. Genet., 2009, 54, 242-247.
39. Wang, J., Williams, C. M., Hegele, R. A.: Compound heterozy- gosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin. Genet., 2005, 67, 175-177.
40. Hegele, R. A., Guy, J., Ban, M. R. ér mtsa: NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis., 2005, 4, 16.
41. Chan, D. C., Watts, G. F., Wang, J. ér mtsai: Variation in Nie- mann-Pick C1-Like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men. Clin. Endocrinol. (Oxf.), 2008, 69, 45-51.
42. Rudkowska, I., AbuMweis, S. S., Nicolle, C. ér mtsa: Association between non-responsiveness to plant sterol intervention and polymorphisms in cholesterol metabolism genes: a case-control study. Appl. Physiol. Nutr. Metab., 2008, 33, 728-734.
43. Polisecki, E., Peter, I., Simon, J. S. ér mtsai: Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. J. Lipid. Res., 2010, 51, 1201-1207.
44. Miettinen, T. A., Gylling, H., Strandberg, T. ér mtsa: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. Br. Med. J., 1998, 316, 1127-1130.
45. McMasters, D. R., Garcia-Calvo, M., Maiorov, V. ér mtsai: Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D- similarity-based virtual screening. Bioorg. Med. Chem. Lett., 2009, 19, 2965-2968.
46. Betters, J. L., Yu, L.: Transporters as drug targets: discovery and development of NPC1L1 inhibitors. Clin. Pharmacol. Ther., 2010, 87, 117-121.